- Home
- NMT vs ALXO Comparison
NMT vs ALXO Comparison
Compare NMT & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMT
- ALXO
- Stock Information
- Founded
- NMT 1993
- ALXO 2015
- Country
- NMT United States
- ALXO United States
- Employees
- NMT N/A
- ALXO N/A
- Industry
- NMT Finance/Investors Services
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- NMT Finance
- ALXO Health Care
- Exchange
- NMT Nasdaq
- ALXO Nasdaq
- Market Cap
- NMT 107.8M
- ALXO 93.7M
- IPO Year
- NMT N/A
- ALXO 2020
- Fundamental
- Price
- NMT $11.47
- ALXO $1.20
- Analyst Decision
- NMT
- ALXO Strong Buy
- Analyst Count
- NMT 0
- ALXO 6
- Target Price
- NMT N/A
- ALXO $3.30
- AVG Volume (30 Days)
- NMT 19.1K
- ALXO 404.1K
- Earning Date
- NMT 01-01-0001
- ALXO 11-07-2025
- Dividend Yield
- NMT 3.21%
- ALXO N/A
- EPS Growth
- NMT N/A
- ALXO N/A
- EPS
- NMT N/A
- ALXO N/A
- Revenue
- NMT N/A
- ALXO N/A
- Revenue This Year
- NMT N/A
- ALXO N/A
- Revenue Next Year
- NMT N/A
- ALXO N/A
- P/E Ratio
- NMT N/A
- ALXO N/A
- Revenue Growth
- NMT N/A
- ALXO N/A
- 52 Week Low
- NMT $9.05
- ALXO $0.40
- 52 Week High
- NMT $10.93
- ALXO $2.27
- Technical
- Relative Strength Index (RSI)
- NMT 42.08
- ALXO 33.50
- Support Level
- NMT $11.42
- ALXO $1.49
- Resistance Level
- NMT $11.60
- ALXO $1.64
- Average True Range (ATR)
- NMT 0.09
- ALXO 0.15
- MACD
- NMT -0.01
- ALXO -0.07
- Stochastic Oscillator
- NMT 23.68
- ALXO 1.30
About NMT Nuveen Massachusetts Quality Municipal Income Fund
Nuveen Massachusetts Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's objective seeks to provide current income exempt from both regular federal and Massachusetts income taxes and to enhance portfolio value relative to the Massachusetts municipal bond market by investing in tax-exempt Massachusetts municipal obligations that are underrated or undervalued or that represent municipal market sectors that are undervalued.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.